Recent Investment Analysts’ Ratings Changes for GW Pharmaceuticals PLC- (GWPH)

Several analysts have recently updated their ratings and price targets for GW Pharmaceuticals PLC- (NASDAQ: GWPH):

  • 2/12/2018 – GW Pharmaceuticals PLC- was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “
  • 2/6/2018 – GW Pharmaceuticals PLC- had its price target lowered by analysts at Bank of America Corp from $154.00 to $149.00. They now have a “buy” rating on the stock.
  • 2/6/2018 – GW Pharmaceuticals PLC- had its price target raised by analysts at Leerink Swann from $153.00 to $157.00. They now have an “outperform” rating on the stock.
  • 2/5/2018 – GW Pharmaceuticals PLC- had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $192.00 price target on the stock, down previously from $208.00. They wrote, “Europe Follows Suit. Following acceptance of the Epidiolex application by the FDA in December, GW announced European acceptance of the application today. In the U.S., the review is expedited, with an advisory panel in 2Q18 and a PDUFA date on June, 27 2018. The company expects a European decision by 1Q19.””
  • 1/30/2018 – GW Pharmaceuticals PLC- was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “
  • 1/23/2018 – GW Pharmaceuticals PLC- had its “buy” rating reaffirmed by analysts at Leerink Swann. They now have a $153.00 price target on the stock.
  • 1/9/2018 – GW Pharmaceuticals PLC- was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/9/2018 – GW Pharmaceuticals PLC- was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “
  • 1/3/2018 – GW Pharmaceuticals PLC- was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “
  • 12/26/2017 – GW Pharmaceuticals PLC- was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “
  • 12/22/2017 – GW Pharmaceuticals PLC- was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of GW Pharmaceuticals PLC- (NASDAQ GWPH) traded down $0.02 during trading on Wednesday, hitting $127.32. The stock had a trading volume of 117,300 shares, compared to its average volume of 401,855. GW Pharmaceuticals PLC- has a one year low of $92.65 and a one year high of $143.37. The company has a market cap of $3,250.00, a PE ratio of -14.34 and a beta of 2.50. The company has a current ratio of 11.44, a quick ratio of 11.34 and a debt-to-equity ratio of 0.01.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.03) by ($0.40). GW Pharmaceuticals PLC- had a negative return on equity of 46.94% and a negative net margin of 1,357.98%. The company had revenue of $7.73 million for the quarter, compared to the consensus estimate of $2.18 million. analysts forecast that GW Pharmaceuticals PLC- will post -9.18 earnings per share for the current fiscal year.

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply